Correlation Between Aerovate Therapeutics and 20825CAF1

Can any of the company-specific risk be diversified away by investing in both Aerovate Therapeutics and 20825CAF1 at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aerovate Therapeutics and 20825CAF1 into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Aerovate Therapeutics and CONOCOPHILLIPS 59 percent, you can compare the effects of market volatilities on Aerovate Therapeutics and 20825CAF1 and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aerovate Therapeutics with a short position of 20825CAF1. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aerovate Therapeutics and 20825CAF1.

Diversification Opportunities for Aerovate Therapeutics and 20825CAF1

-0.58

Correlation Coefficient

Aerovate Therapeutics  20825CAF1

Excellent diversification

The 3 months correlation between Aerovate and 20825CAF1 is -0.58. Overlapping area represents the amount of risk that can be diversified away by holding Aerovate Therapeutics and CONOCOPHILLIPS 59 percent in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CONOCOPHILLIPS 59 percent and Aerovate Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aerovate Therapeutics are associated (or correlated) with 20825CAF1. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CONOCOPHILLIPS 59 percent has no effect on the direction of Aerovate Therapeutics i.e., Aerovate Therapeutics and 20825CAF1 go up and down completely randomly.

Pair Corralation between Aerovate Therapeutics and 20825CAF1

Given the investment horizon of 90 days Aerovate Therapeutics is expected to generate 4.67 times more return on investment than 20825CAF1. However, Aerovate Therapeutics is 4.67 times more volatile than CONOCOPHILLIPS 59 percent. It trades about 0.16 of its potential returns per unit of risk. CONOCOPHILLIPS 59 percent is currently generating about -0.1 per unit of risk. If you would invest  190.00  in Aerovate Therapeutics on September 13, 2024 and sell it today you would earn a total of  70.00  from holding Aerovate Therapeutics or generate 36.84% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	93.65%
Values	Daily Returns

Aerovate Therapeutics  vs.  CONOCOPHILLIPS 59 percent

Aerovate Therapeutics

Risk-Adjusted Performance

12 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Aerovate Therapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of rather fragile basic indicators, Aerovate Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.

CONOCOPHILLIPS 59 percent

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days CONOCOPHILLIPS 59 percent has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, 20825CAF1 is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Aerovate Therapeutics and 20825CAF1

The main advantage of trading using opposite Aerovate Therapeutics and 20825CAF1 positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aerovate Therapeutics position performs unexpectedly, 20825CAF1 can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in 20825CAF1 will offset losses from the drop in 20825CAF1's long position.

The idea behind Aerovate Therapeutics and CONOCOPHILLIPS 59 percent pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.